TEST_2DPAGE Release 3 Feb 2005 ID HC_HUMAN; PRELIMINARY 2DG. AC Z02760; X0|2759; NP_999999.1; DT 01-AUG-2003 (REL. 01, CREATED) DT 01-NOV-2004 (REL. 02, LAST MAP ANNOTATION) DT 01-FEB-2005 (REL. 03, LAST UPDATE) DE ALPHA-1-MICROGLOBULIN / INTER-ALPHA-TRYPSIN INHIBITOR LIGHT CHAIN DE (PROTEIN HC) (HI30). GN N/A OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo. OX NCBI_TaxID=9606. IM PLASMA. RN [1] RP MAPPING ON GEL. RA ANDERSON N.L.; RL PERSONAL COMMUNICATION (1993). CC -!- WARNING: PLEASE, NOTE THAT THIS ENTRY IS PURELY FICTITIOUS! IT IS ONLY USED FOR TEST PURPOSE. CC -!- SUBUNIT: SINGLE CHAIN. 2D -!- MASTER: PLASMA; 2D -!- PI/MW: SPOT 89=4.86/33544; 2D -!- PI/MW: SPOT 111=4.96/32167; 2D -!- PI/MW: SPOT 112=5.07/31046; 2D -!- PI/MW: SPOT 408=5.12/23908; 2D -!- PEPTIDE MASSES: SPOT 408: 869.468; 924.448; 1335.708; 1399.114; 1412.129; 2D 1465.729; 1472.785; 1673.868; 1691.913; 1947.029; 2203.998; 2425.211; TRYPSIN. 2D -!- PEPTIDE MASSES: SPOT 112: 769.468 (1.09); 824.448 (2.67); 1235.708 (3.17); 1312.129 (1.2); 2D 1365.729 (2.91); 1372.785 (4.61); 1573.868 (7.11); 1591.913 (0.99); 2325.211 (5.14); TRYPSIN. 2D -!- PEPTIDE MASSES: SPOT 112: 669.468 (1.09); 724.448 (2.67); 1135.708 (3.17); 1212.129 (1.2); 2D 1265.729 (2.91); 1272.785 (4.61); 1473.868 (7.11); 1491.913 (0.99); 2225.211 (5.14); TRYPSIN. 2D -!- MASS SPECTROMETRY: SPOT 112: [2] 669.468 (1.09); 324.448 (2.67); 435.708 (3.17); 512.129 (1.2); 2D 565.729 (2.91); 272.785 (4.61); 473.868 (7.11); 491.913 (0.99); 225.211 (5.14). 2D -!- PEPTIDE SEQUENCES: SPOT 112: (R)SLDMoxDSIIAEVK(A),252-263; 2D (R)ASLEAAIADAEQR(G),328-340; (R)LEGLTDEINFLR(Q),213-224. 2D -!- PEPTIDE SEQUENCES: SPOT 112: (S)RLDMoxDSIIAEVK(K),352-363; 2D (S)SSLEAAIADAEQR(E),428-440. 2D -!- MAPPING: Peptide mass fingerprinting; SPOT 112: Tandem mass spectrometry. 2D -!- NORMAL LEVEL: 34-90 MG/L. 2D -!- PATHOLOGICAL LEVEL: Increased during renal insufficiency and tubular proteinuria; 2D SPOT 11*: Decreased during renal insufficiency. DR Swiss-Prot; P02760; HC_HUMAN. // AC P12345; 2D -!- MASTER: PLASMA; 2D -!- PI/MW: SPOT 397=4.43/32375; // AC ZI|GI.MINIMAL; 2D -!- MASTER: PLASMA; 2D -!- PI/MW: SPOT 397=4.43/32375; DR Swiss-Prot; P00853; - DR NCBI_Protein; 31543902; - // ID CRP_HUMAN; PRELIMINARY 2DG. AC Z02741; DT 01-NOV-2004 (REL. 01, CREATED) DT 01-NOV-2004 (REL. 01, LAST UPDATE) DE C-REACTIVE PROTEIN PRECURSOR (EC 1.1.1.9). GN N/A OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo. OX NCBI_TaxID=9606. IM PLASMA. RN [1] RP MAPPING ON GEL. RA ANDERSON N.L.; RL PERSONAL COMMUNICATION (1993). CC -!- WARNING: PLEASE, NOTE THAT THIS ENTRY IS PURELY FICTITIOUS! IT IS ONLY USED FOR TEST PURPOSE. CC -!- SUBUNIT: HOMOPENTAMER. 2D -!- MAPPING COMMENT: CROSS-SPECIES IDENTIFICATION 2D (Swiss-Prot; PGMU_RAT; P38652). 2D -!- MASTER: PLASMA; 2D -!- PI/MW: SPOT 408=5.12/23908; 2D -!- PEPTIDE MASSES: SPOT 408: 912.468; 345.448; 1234.708; 1345.114; 1499.129; TRYPSIN. 2D -!- MAPPING: Immunobloting [1]. 2D -!- NORMAL LEVEL: 2-5 MG/L. 2D -!- PATHOLOGICAL LEVEL: Increased during acute and chronic bacterial infections, 2D cell necrosis and hodgkins disease. DR SWISS-PROT; P02741; CRP_HUMAN. // ID APD_HUMAN; PRELIMINARY 2DG. AC Z05090; DT 01-AUG-2003 (REL. 01, CREATED) DT 01-AUG-2003 (REL. 01, LAST UPDATE) DE APOLIPOPROTEIN D. GN (TUFB OR B3980) AND (GND OR SA1342 OR MW1464). OS Mus musculus (Mouse). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus. OX NCBI_TaxID=10090. IM PLASMA. RN [1] RP MAPPING ON GEL. RG The "Fictitious" Sequencing Consortium for PROTEIN Isolation and Characterization; RG Somewhere Laboratories; RA ANDERSON N.L., ANDERSON N.G.; RL PROC. NATL. ACAD. SCI. USA, 74:5421-5425(1977). CC -!- WARNING: PLEASE, NOTE THAT THIS ENTRY IS PURELY FICTICIOUS! IT IS ONLY USED FOR TEST PURPOSE. CC -!- SUBUNIT: HOMODIMER. 2D -!- MASTER: PLASMA; 2D -!- PI/MW: SPOT 397=4.43/32375; 2D -!- PI/MW: SPOT 465=4.88/27200; 2D -!- MAPPING: Immunobloting [1]. 2D -!- MAPPING: MALDI tandem mass spectrometry [1]; SPOT 397: Peptide 2D mass fingerprinting [1]. 2D -!- NORMAL LEVEL: 80-100 MG/L. 2D -!- PATHOLOGICAL LEVEL: Increased during type I hyperlipaemia. DR Swiss-Prot; P05090; - // ID TCTP_FICTITIOUS; PRELIMINARY 2DG. AC Z13693; DT 01-AUG-2003 (REL. 01, CREATED) DT 01-AUG-2003 (REL. 01, LAST UPDATE) DE TRANSLATIONALLY CONTROLLED TUMOR PROTEIN (TCTP) (P23). GN Name=Ser99Da; Synonyms=SER1; ORFNames=CG7877; GN and GN Name=Ser99Db; Synonyms=SER2; ORFNames=CG15519; GN and GN Name=hns; Synonyms=bglY, cur, drdX, hnsA, msyA, osmZ, pilG, topS; GN OrderedLocusNames=b1237, c1701, z2013, ECs1739; OS Mus musculus (Mouse). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus. OX NCBI_TaxID=10090. IM PLASMA, PLASMA2. RN [1] RP MAPPING ON GEL. RX MEDLINE=93162045; PubMed=9145897; RX DOI=10.1002/pmic.200300483; RA HOCHSTRASSER D.F., FRUTIGER S., PAQUET N., BAIROCH A., RAVIER F., RA PASQUALI C., SANCHEZ J.-C., TISSOT J.-D., BJELLQVIST B., VARGAS R., RA APPEL R.D., HUGHES G.J.; RT "Human liver protein map: a reference database established by microsequencing and gel comparison."; RL ELECTROPHORESIS, 13:992-1001(1992). RN [2] RP MAPPING ON GEL. RA SANCHEZ J.-C., GOLAZ O.G., PAQUET N., FRUTIGER S., HUGHES G.J., RA PASQUALI C., BAIROCH A., APPEL R.D., HOCHSTRASSER D.F.; RL ELECTROPHORESIS 0:0-0(1993). CC -!- WARNING: PLEASE, NOTE THAT THIS ENTRY IS PURELY FICTITIOUS! IT IS ONLY USED FOR TEST PURPOSE. CC -!- IT CONTAINS 2 GELS OF DIFFERENT SPECIES FOR SIMPLIFICATION. PLEASE, NOTE THAT THIS IS NOT ALLOWED! 2D -!- MASTER: PLASMA; 2D -!- PI/MW: SPOT 408=5.12/23908; 2D -!- MASTER: PLASMA2; 2D -!- PI/MW: SPOT 397=4.85/22158; 2D -!- AMINO ACID COMPOSITION: SPOT 397: B=12, Z=13.7, S=3.7, 2D H=0.3, G=11.8, T=5.2, A=11.3, P=3.5, Y=2.5, R=3.6, V=9.4, M=1.5, I=6.1, 2D L=7.2, F=2, K=6.3; 2D -!- AMINO ACID COMPOSITION: SPOT 397: B=9, Z=11.7, S=8.7, 2D H=1.3, G=12.8, T=6.2, A=12.3, P=1.5, Y=1.5, R=1.6, V=1.4, M=1.5, I=12.1, 2D L=1.2, F=2, K=1.3; 2D -!- PEPTIDE SEQUENCES: SPOT 397: (R)SLDMoxDSIIAEVK(A),252-263; 2D (R)ASLEAAIADAEQR(G),328-340; (R)LEGLTDEINFLR(Q),213-224. 2D -!- PEPTIDE MASSES: SPOT 397: 669.468 (1.09); 724.448 (2.67); 1135.708 (3.17); 1212.129 (1.2); 2D 1265.729 (2.91); 1272.785 (4.61); 1473.868 (7.11); 1491.913 (0.99); 2225.211 (5.14); TRYPSIN. 2D -!- PEPTIDE SEQUENCES: SPOT 397: (S)RLDMoxDSIIAEVK(K),352-363; 2D (S)SSLEAAIADAEQR(E),428-440. 2D -!- MAPPING: Microsequencing [1]; Amino acid composition analysis [1]; DR Swiss-Prot; P13693; TCTP_HUMAN. DR SWISS-2DPAGE; P13693; TCTP_HUMAN. DR GO; GO:0000002; P:mitochondrial genome maintenance; IMP; possible more information. // AC P19354; 2D -!- MASTER: PLASMA2; 2D -!- PI/MW: SPOT 397=4.43/32375; 2D -!- MASS SPECTROMETRY: SPOT 397: [1] 769.468 (1.09); 524.448 (2.67); 435.708 (3.17); 512.129 (1.2); 2D 565.729 (2.91); 272.785 (4.61); 473.868 (7.11); 491.913 (0.99); 225.211 (5.14). // AC P02990; 2D -!- MASTER: PLASMA; 2D -!- PI/MW: SPOT 397=4.43/32375; //